БЕСКОНСЕРВАНТНАЯ ФОРМА ФИКСИРОВАННОЙ КОМБИНАЦИИ БИМАТОПРОСТА И ТИМОЛОЛА В ПОВЫШЕНИИ КОМПЛАЕНСА И ЭФФЕКТИВНОСТИ ЛЕЧЕНИЯ ПАЦИЕНТОВ С ПЕРВИЧНОЙ ОТКРЫТОУГОЛЬНОЙ ГЛАУКОМОЙ
https://doi.org/10.21516/2072-0076-2018-11-2-95-101
Аннотация
Цель обзора - анализ данных новейших клинических исследований эффективности и безопасности фиксированных комбинаций как средства первоочередного выбора в терапии пациентов с первичной открытоугольной глаукомой. Анализируются данные о применении фиксированной комбинации биматопроста 0,03% и тимолола 0,5%, а также влияние применения данной фиксированной комбинации без консерванта на повышение приверженности к лечению, сохранение зрительных функций и повышение качества жизни пациентов на всех стадиях глаукомного процесса. Для цитирования: Лоскутов И.А., Корнеева А.В. Бесконсервантная форма фиксированной комбинации биматопроста и тимолола в повышении комплаенса и эффективности лечения пациентов с первичной открытоугольной глаукомой. Российский офтальмологический журнал. 2018; 11(2): 95-101. doi: 10.21516/2072-0076-2018-11-2-95-101.
Об авторах
И. А. Лоскутов
Офтальмологическое отделение Научно-практического центра ООО «РЖД», Москва
Россия
Россия
А. В. Корнеева
ООО «Три-З», Москва
Россия
Россия
Список литературы
1. Freeman E.E., Munoz B., West S.K., Jampel H.D., Friedman D.S. Glaucoma and quality of life: the Salisbury eye evaluation. Ophthalmol. 2008; 115(2): 233-38. doi.org/10.1016/j.ophtha.2007.04.050
2. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 4th ed. Savona, Italy: PubliComm; 2014. doi.org/10.1136/bjophthalmol-2016-egsguideline.001
3. Pillunat L.E., Eschstruth P., Haesemeyer S., Theren U., et al. Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice. Clinic. Ophthalmol. 2016; 10: 1759-65. doi.org/10.2147/opth.s103084
4. Hyman L.G., Komaroff E., Heijl A., Bengtsson B., Leske M.C. Early Manifest Glaucoma Trial Group. Treatment and vision-related quality of life in the early manifest glaucoma trial. Ophthalmol. 2005; 112(9): 1505-13. doi.org/10.1016/j.ophtha.2005.03.028
5. Heijl A., Bengtsson B., Chauhan B.C., Lieberman M.F, et al. A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. Ophthalmol. 2008; 115: 1557-65. doi:10.1016/j. ophtha.2008.02.005
6. Gillespie B.W., Musch D.C., Guire K.E., Mills R.P., et al. CIGTS (Collaborative Initial Glaucoma Treatment Study) Study Group. The collaborative initial glaucoma treatment study: Baseline visual field and test-retest variability. Invest. Ophthalmol. Vis. Sci. 2003; 44: 2613-20. doi.org/10.1167/iovs.02-0543
7. Chauhan B.C., Mikelberg F.S., Balaszi A.G., LeBlanc R.P., et al. Canadian Glaucoma Study Group; Canadian Glaucoma Study: 2. Risk factors for the progression of open-angle glaucoma. Arch. Ophthalmol. 2008; 126: 1030-36. doi:10.1001/ archopht.126.8.1030
8. Adatia F.A., Damji K.F. Chronic open-angle glaucoma. Review for primary care physicians. Can. Fam. Physician. 2005; 51: 1229-37.
9. Bagnis A., Papadia M., Scotto R., Traverso C.E. Current and emerging medical therapies in the treatment of glaucoma. Expert. Op. in Emerg. Drugs. 2011; 16(2): 293-307. doi.org/10.1517/14728214.2011.563733
10. Heijl A., Leske M.C., Bengtsson B., et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch. Ophthalmol. 2002; 120(10): 1268-79. doi.org/10.1001/archopht.120.10.1268
11. Resnikoff S., Pascolini D., Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004; 82(11): 844-51. doi.org/10.2471/blt.07.041210
12. Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 2006; 90(3): 262-67. doi.org/10.1136/bjo.2005.081224
13. Garway-Heath D.F., Crabb D.P., Bunce C., Lascaratos G, et al. Latanoprost for open-angle glaucoma (UKGTS): A randomised, multicentre, placebo-controlled trial. Lancet. 2015; 385: 1295-1304. doi: 10.1016/S0140-6736(14)62111-5
14. van der Valk R., Webers C.A., Schouten J.S., Zeegers M.P., et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: A meta-analysis of randomized clinical trials. Ophthalmol. 2005; 112: 1177-85. doi.org/10.1016/j.ophtha.2005.01.042
15. Konstas A.G., Maltezos A.C., Gandi, S., Hudgins, A.C., Stewart, W.C. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am. J. Ophthalmol. 1999; 128: 15-20. doi.org/10.1016/s0002-9394(99)00073-2
16. Aptel F., Cucherat M., Denis P. Efficacy and tolerability of prostaglandin analogs: A meta-analysis of randomized controlled clinical trials. J. Glaucoma. 2008; 17: 667-73. doi:10.1097/IJG. 0B013e3181666557
17. Inoue K., Shiokawa M., Fujimoto T., Tomita G. Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma. Clin. Ophthalmol. 2014; 8: 1179-83. doi.org/10.2147/opth.s60538
18. Sato S., Hirooka K., Baba T., Mizote M., et al. Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma. J. Ocul. Pharmacol. Ther. 2011; 27: 499-502. doi.org/10.1089/jop.2011.0020
19. Ciancaglini M., Caprineto P., Agnifili L., Nubile M., et al. A 12-week study evaluating the efficacy of bimatoprost 0.03% in patients with pseudoexfoliative and open-angle glaucoma. European J. Ophthalmol. 2009; 19(4): 584-600. doi.org/10.1177/112067210901900412
20. Pohjanpelto P. Long-term prognosis of visual field in glaucoma simplex and glaucoma capsulare. Acta Ophthalmol. (Copenh). 1985; 63: 418-23.
21. Konstas A.G., Mantziris D.A., Stewart W.C. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch. Ophthalmol. 1997; 115: 182-5. doi.org/10.1001/archopht.1997.01100150184006
22. Takmaz T., Can I., Gurdal C., Kurkcuoglu P., et al. Effect of bimatoprost on intraocular pressure after phacoemulsification in eyes with exfoliation syndrome. Acta Ophthalmol. Scand. 2007; 85(3): 262-6. doi.org/10.1111/j.1600-0420.2006.00835.x
23. Bömer T.G., Lagreze W-D.A, Funk J. Intraocular pressure rise after phacoemulsification with posterior chamber lens implantation: effect of prophylactic medication, wound closure, and surgeon’s experience. Br. J. Ophthalmol. 1998; 12: 809-13. doi.org/10.1136/bjo.79.9.809
24. Prum B.E., Rosenberg L.F., Gedde S.J. et al. Primary open-angle glaucoma. Ophthalmol. 2016; 123(1): 41-111. doi.org/10.1016/j.ophtha.2015.10.053
25. Mishima H.K., Kiuchi Y., Takamatsu M., Racz P., Bito L.Z. Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv. Ophthalmol. 1997; 41(Suppl 2): 139-44. doi.org/10.1016/s0039-6257(97)80021-5
26. Orzalesi N., Rossetti L., Invernizzi T., Bottoli A., Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest. Ophthalmol. Vis. Sci. 2000; 41(9): 2566-73. doi.org/10.1016/s0002-9394(00)00751-0
27. Lewis R.A., Gross R.L., Sall K.N., Schiffman R.M., et al. The safety and efficacy of bimatoprost/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J. Glaucoma. 2010; 19(6): 424-426. doi.org/10.1097/ijg.0b013e3181bdb586
28. Higginbotham E.J. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin. Ophthalmol. 2010; 4(1): 1-9. doi.org/10.2147/opth.s6645
29. Куроедов А.В. Перспективы применению комбинированных антиглаукомных препаратов (обзор литературы). Клиническая офтальмология. 2007; 4: 176-81.
30. Еричев В.П. Гипотензивная терапия первичной открытоугольной глаукомы фиксированными комбинациями лекарственных средств: метод. рекомендации. Москва: Апрель; 2012.
31. Centofanti M., Oddone F., Gandolfi S., et al. Comparison of travoprost and bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination. Am. J. Ophthalmol. 2010; 150: 575-80. doi.org/10.1016/j.ajo.2010.05.003
32. Stalmans I., Oddobe F., Cordeiro M. F., Hommer A., et al. Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial. Graefes Arch. Clin. Exp. Ophthalmol. 2016; 254: 1151-58. doi.org/10.1007/s00417-016-3299-9
33. Aptel F., Cucherat M., Denis P. Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur. J. Ophthalmol. 2012; 22: 5-18. doi.org/10.5301/ejo.2011.8351
34. Pfennigsdorf S., de Jong L., Makk S., et al. A combined analysis of five observational studies evaluating the efficacy and tolerability of bimatoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension. Clin. Ophthalmol. 2013; 7: 1219-1225. doi.org/10.2147/opth.s41885
35. Patel S.C., Spaeth G.L. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995; 26(3): 233-236.
36. Olthoff C.M, Schouten J.S., Borne B.W. van de, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmol. 2005; 112(6): 953-961. doi.org/10.1016/j.ophtha.2004.12.035
37. Липатов Д.В., Чиcтяков Т.А., Кузьмин А.Г., Толкачева А.А. Оценка эффективности терапии препаратом Ганфорт у пациентов с вторичной неоваскулярной глаукомой при сахарном диабете. Вестник офтальмологии. 2014; 3: 45-8.
38. Stalmans I., Sunaric Mégevand G., Cordeiro M.F., Hommer A., et al. Preservative-free treatment in glaucoma: Who, when, and why. Eur. J. Ophthalmol. 2013: 23: 518-525. doi:10.5301/ejo.5000270
39. Gobbels M., Spitznas M. Influence of artificial tears on corneal epithelium in dry eye syndrome. Graefes Arch. Clin. Exp. Ophthalmol. 1989; 227: 139-141. https://doi.org/10.1007/bf02169786
40. Labbe A., Terry O., Brasnu E., Van W.C., Baudouin C. Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Cornea. 2012; 31(9): 994-99. doi.org/10.1097/ico.0b013e31823f8cb6
41. Broadway D.C., Chang L.P. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J. Glaucoma. 2001; 10: 237-49. doi.org/10.1097/00061198-200106000-00017
42. Breusegem C., Spielberg L., Van Ginderdeuren R. et al. Preoperative nonsteroidal antiinflammatory drug or steroid and outcomes after trabeculectomy: a randomized controlled trial. Ophthalmol. 2010; 117: 1324- 30. doi.org/10.1016/j.ophtha.2009.11.038
43. Rossi G.C., Pasinetti G.M., Scudeller L., et al. Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients. Eur. J. Ophthalmol. 2013; 23(3): 296-302. doi.org/10.5301/ejo.5000220
44. Baudouin C., Renard J.P., Nordmann J.P., et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur. J. Ophthalmol. 2013; 23: 47-54. doi.org/10.5301/ejo.5000181
45. Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur. J. Ophthalmol. 2007; 17(3): 341-349. doi.org/10.1177/112067210701700311
46. Pfennigsdorf S., Eschstruth P., Häsemeye S., Feuerhake C., et al. Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice. Clinic. Ophthalmol. 2016; 10: 1837-46. doi.org/10.2147/opth.s106159
47. Quaranta L., Biagioli E., Riva I, et al. Prostaglandin analogs and timololfixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J. Ocul. Pharmacol. Ther. 2013; 29(4): 382-89. doi.org/10.1089/jop.2012.0186
48. Cordeiro M.F., Goldberg I., Schiffman R., Bernstein P., Bejanian M. Efficacy of a preservative-free formulation of fixedcombination bimatoprost and timolol (Ganfort PF) in treatment-naïve patients vs previously treated patients. Clin. Ophthalmol. 2015; 9: 1605-11. doi.org/10.2147/opth.s84163
49. Goldberg I., Gil Pina R., Lanzagorta-Aresti A., Schiffman R.M., et al. Bimatoprost 0.03%/timolol 0.5% preservativefree ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. Br. J. Ophthalmol. 2014; 98(7): 926-31. doi.org/10.1136/bjophthalmol-2013-304064
50. de Jong C., Stolwijk T., Kuppens E., de Keizer R., van Best J. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. 1994; 232(4): 221-24. doi.org/10.1007/bf00184009
51. Bron A., Velasque L., Rebica H., Pouliquen P., et al. Comparaison du timolol sans conservateur et du timolol à délivrance prolongée donnés une fois par jour en association à du latanoprost. [Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost]. J. Fr. Ophthalmol. 2004; 27(9): 971-77. doi.org/10.1016/s0181-5512(04)96251-1 (In French)
52. Frezzotti P., Fogagnolo P., Haka G., et al. In vivo confocal microscopy of conjunctiva in preservative-free timolol 0.1% gel formulation therapy for glaucoma. Acta Ophthalmol. 2014; 92(2): 133-40. doi.org/10.1111/aos.12261
53. Manni G., Centofanti M., Oddone F., Parravano M., Bucci M.G. Interleukin-1β tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers. Am. J. Ophthalmol. 2005; 139(1): 72-7. doi.org/10.1016/j.ajo.2004.08.028
54. Mastropasqua L., Agnifili L., Fasanella V., et al. Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study. Acta Ophthalmol. 2013; 91(5): 397-405. doi.org/10.1111/aos.12131
55. Uusitalo H., Kaarniranta K., Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol. Suppl. (Oxf). 2008; 242: 7-13. doi.org/10.1111/j.1755-3768.2008.01380.x
56. Pisella P.J., Pouliquen P., Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br. J. Ophthalmol. 2002; 86(4): 418-23. doi.org/10.1136/bjo.86.4.418
57. Bron A., Chiambaretta F., Pouliquen P., Rigal D., Rouland J.F. Intérêt de la substitution d’un traitement journalier de 2 instillations de timolol par 1 instillation quotidienne de bêtabloquant non conservé chez des patients présentant un glaucome chronique ou une hypertonie oculaire [Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertension]. J. Fr. Ophthalmol. 2003; 26(7): 668-74. doi.org/10.1016/s0181-5512(06)73821-9 (In French)
58. Okabe K., Kimura H., Okabe J., et al. Effect of benzalkonium chloride on transscleral drug delivery. Invest. Ophthalmol. Vis. Sci. 2005; 46(2): 703-8. doi.org/10.1167/iovs.03-0934
59. Desbenoit N., Schmitz-Afonso I., Baudouin C., et al. Localisation and quantification of benzalkonium chloride in eye tissue by TOF-SIMS imaging and liquid chromatography mass spectrometry. Anal. Bioanal Chem. 2013; 405(12): 4039-49. https://doi.org/10.1007/s00216-013-6811-7
Рецензия
Для цитирования:
Лоскутов И.А., Корнеева А.В. БЕСКОНСЕРВАНТНАЯ ФОРМА ФИКСИРОВАННОЙ КОМБИНАЦИИ БИМАТОПРОСТА И ТИМОЛОЛА В ПОВЫШЕНИИ КОМПЛАЕНСА И ЭФФЕКТИВНОСТИ ЛЕЧЕНИЯ ПАЦИЕНТОВ С ПЕРВИЧНОЙ ОТКРЫТОУГОЛЬНОЙ ГЛАУКОМОЙ. Российский офтальмологический журнал. 2018;11(2):95-101. https://doi.org/10.21516/2072-0076-2018-11-2-95-101
For citation:
Loskoutov I.A., Korneeva A.V. PRESERVATIVE-FREE FIXED COMBINATION OF BIMATOPROST AND TIMOLOL IN THE EVOLUTION OF COMPLIANCE AND TREATMENT EFFECTIVENESS IN PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA. Russian Ophthalmological Journal. 2018;11(2):95-101. (In Russ.) https://doi.org/10.21516/2072-0076-2018-11-2-95-101
Просмотров: 731
Послать статью по эл. почте 